Pilot Study of Posaconazole in Crohn's Disease

Inclusion Criteria: * Male or female patients aged 18 years and older, inclusive based on the date of the screening visit. * A diagnosis of CD with minimum disease duration of 6 months with involvement of the ileum and/or colon documented on colonoscopy * Have an endoscopically-confirmed active Crohn's disease with active disease defined by SES-CD \> 6 (\>4 if ileal only), AND active symptoms of Crohn's disease (CDAI score \>220) * Homozygous for CARD9 S12N risk allele, without the protective exon 11 polymorphism * Subjects receiving oral aminosalicylates (at a stable dose for 2 weeks prior to baseline), immunomodulators (at a stable dose for 4 weeks prior to baseline), anti-TNF, anti IL12/23, or anti-integrin therapy (at stable maintenance doses for \> 8 weeks) may continue their use during the study. * Subjects receiving oral corticosteroids may continue their use during the study provided the dose (prednisone up to 20 mg/day, budesonide up to 9 mg/day) has been stable for two weeks prior to screening. * Have had age-appropriate and disease-duration-appropriate colon cancer screening1 without unresected dysplasia. * Women of childbearing age, excluding those with prior bilateral tubal ligation or at least one-year post-menopause, must not be pregnant, lactating, or planning to become pregnant. They must agree to use effective contraception throughout the study period. * Subjects must be able to provide informed consent and understand, agree with, and be able to adhere to d…